Life sciences companies are increasingly embracing decentralised and virtual study designs – where patient consent and data are captured using their own devices from wherever they are located.
Back in 2012, London-based uMotif started as a search for a simple way to help people capture data about their health. Through simple and web mobile apps, people can track and monitor their health and choose to share their data with their clinicians, carers, and others to improve care.
The UK patient-centric data capture software company has raised £5 million (approx €5.6 million) in a Series A investment round led by existing investor AlbionVC. Others including Oslo-based DNV-GL and existing angel investors also participated in the round.
“We’re excited to help our customers implement patient-centered research designs by using the uMotif platform to capture high-quality data,” says Bruce Hellman, CEO, and Co-Founder of uMotif. “This new funding will rapidly accelerate our development and will ultimately help our customers to get new therapies to patients faster”.
The company is planning to use the funding to further develop its patient-centric and decentralised approach to clinical studies and enable expansion into new study types and more high-demand territories. On top of that, it will enable further growth and geographical expansion.
Decentralised and patient-centric approaches
Founded by Bruce Hellman and Ben James, uMotif’s cloud-based platform is trusted by the world’s leading pharmaceutical and biotech companies to capture clinical research data.
With studies taking place in 26 countries from clinical to real-world settings, and across more than 25 therapeutic areas – from dermatology and rare disease to oncology and cardiology, uMotif’s focus is to foster a highly engaging patient experience to capture larger volumes of higher quality data.
Dr. Andrew Elder, Deputy Managing Partner at AlbionVC says: “Now more than ever, having access to reliable patient data during clinical trials is crucial. uMotif’s platform is built with patients in mind; designed to help academics, researchers, and healthcare professionals to capture the best quality data in a way that suits the participants. It’s a win-win for all stakeholders and the platform has the potential and momentum to revolutionise the speed and efficiency with which therapies can reach and help millions of patients.”
Kaare Helle, Venture Director at DNV GL says: “Healthcare is dependent on digital transformation if it is to move towards being a more sustainable sector. uMotif has developed a digital platform that can support new models of clinical trials while also ensuring that the patient voice is heard. We have been impressed with the platform and the management team at uMotif who are responsive to customer and patient needs and passionate about making a difference.”
Main image credits: uMotif